Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AIMS: ST-elevation myocardial infarction is associated with high levels of cardiac sympathetic drive and release of the co-transmitter neuropeptide Y (NPY). We hypothesized that despite beta-blockade, NPY promotes arrhythmogenesis via ventricular myocyte receptors. METHODS AND RESULTS: In 78 patients treated with primary percutaneous coronary intervention, sustained ventricular tachycardia (VT) or fibrillation (VF) occurred in 6 (7.7%) within 48 h. These patients had significantly (P 

Original publication

DOI

10.1093/eurheartj/ehz852

Type

Journal article

Journal

Eur Heart J

Publication Date

14/06/2020

Volume

41

Pages

2168 - 2179

Keywords

Myocardial infarction, Neuropeptide Y, Percutaneous coronary intervention, Ventricular fibrillation, Ventricular tachycardia, Animals, Heart, Humans, Neuropeptide Y, Percutaneous Coronary Intervention, Rats, ST Elevation Myocardial Infarction, Ventricular Fibrillation